Item


Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment

The recent identification of HER2 gene amplification as a novel predictor of resistance to the EGFR (HER2)-targeted antibody cetuximab and of response to combination therapies against EGFR and HER2 in wild-type KRAS tumor settings may represent a further step toward personalized medicine for patients with colorectal cancer. Herein, we show that transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification is a molecular phenomenon that takes place in EGFR-dependent, wild-type KRAS squamous cell carcinoma (SCC) cells that acquire resistance to cetuximab. Since cetuximab activity against cetuximab-refractory SCC cells can be fully restored in the presence of the anti-HER2 monoclonal antibody trastuzumab, our findings suggest that, beyond HER2 gene amplification, we might need to redefine the threshold values for HER2 positivity to improve the accuracy of the selection of cetuximab-refractory patients with wild-type KRAS that may benefit from receiving a cetuximab/trastuzumab combination

© Oncology Reports, 2012, vol. 27, núm. 6, p. 1887-1892

Spandidos Publications

Author: Oliveras Ferrarós, Cristina
Massaguer i Vall-llovera, Anna
Vázquez Martín, Alejandro
Carrion Salip, Dolors
Queralt, Bernardo
Cufí González, Sílvia
Martin Castillo, Begoña
Bosch Barrera, Joaquim
Brunet i Vidal, Joan
Llorens Duran, Rafael de
Menéndez Menéndez, Javier Abel
Date: 2012
Abstract: The recent identification of HER2 gene amplification as a novel predictor of resistance to the EGFR (HER2)-targeted antibody cetuximab and of response to combination therapies against EGFR and HER2 in wild-type KRAS tumor settings may represent a further step toward personalized medicine for patients with colorectal cancer. Herein, we show that transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification is a molecular phenomenon that takes place in EGFR-dependent, wild-type KRAS squamous cell carcinoma (SCC) cells that acquire resistance to cetuximab. Since cetuximab activity against cetuximab-refractory SCC cells can be fully restored in the presence of the anti-HER2 monoclonal antibody trastuzumab, our findings suggest that, beyond HER2 gene amplification, we might need to redefine the threshold values for HER2 positivity to improve the accuracy of the selection of cetuximab-refractory patients with wild-type KRAS that may benefit from receiving a cetuximab/trastuzumab combination
Format: application/pdf
ISSN: 1021-335X (versió paper)
1791-2431 (versió electrònica)
Document access: http://hdl.handle.net/10256/8264
Language: eng
Publisher: Spandidos Publications
Collection: Reproducció digital del document publicat a: http://www.spandidos-publications.com/or/27/6/1887
Articles publicats (D-B)
Is part of: © Oncology Reports, 2012, vol. 27, núm. 6, p. 1887-1892
Rights: Tots els drets reservats
Subject: Càncer -- Tractament
Cancer -- Treatment
Recte -- Càncer
Rectum -- Cancer
Medicaments antineoplàstics
Antineoplastic agents
Title: Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
Type: info:eu-repo/semantics/article
Repository: DUGiDocs

Subjects

Authors


Warning: Unknown: write failed: No space left on device (28) in Unknown on line 0

Warning: Unknown: Failed to write session data (files). Please verify that the current setting of session.save_path is correct (/var/lib/php5) in Unknown on line 0